Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
Sponsor: RiboX Therapeutics Ltd.
Summary
The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.
Official title: A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Early Efficacy of RXIM002, in Patients With Relapsed or Refractory Autoimmune Cytopenias
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2027-02-01
Completion Date
2029-12-31
Last Updated
2026-08-14
Healthy Volunteers
No
Interventions
RXIM002
Targeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)